Market Overview

Bacterin Study Shows OsteoSponge Equivalence to rhBMP-2 in Spinal Fusion

Bacterin International Holdings, Inc. (NYSE: BONE) reported results of a two-year study for OsteoSponge®.

Used in conjunction with the patients' own bone marrow aspirate, OsteoSponge is a highly effective osteoinductive and osteoconductive bone scaffold that aids in spinal fusion. The study was conducted in collaboration with researchers at the Salt Lake Orthopaedic Clinic, Spine Surgery of Salt Lake City.

The two-year post-operative, clinical data showed OsteoSponge to be equivalent to rhBMP-2 in achieving an interbody fusion based upon radiographic assessment, CT scans, and quality of life outcomes. Additionally, patients receiving the OsteoSponge graft reported statistically significant less leg pain at one year relative to the rhBMP-2 group.

Posted-In: News FDA

 

Related Articles (BONE)

Around the Web, We're Loving...

Get Benzinga's Newsletters